Darvadstrocel

CHEMBL4298180 Phase 4 Approved Cell
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A cell therapy consisting of expanded adipose-derived stem cells used to treat complex perianal fistulas in patients with Crohn's disease. The cells are injected directly into the fistula to promote healing and closure.

Therapeutic Areas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A cell therapy consisting of expanded adipose-derived stem cells used to treat complex perianal fistulas in patients with Crohn's disease. The cells are injected directly into the fistula to promote healing and closure.

Yes, Darvadstrocel is an approved drug. It has reached clinical phase 4. It is classified as a Cell.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298180. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.